Development PipelineSGN-BB228

an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNBB228-001: Advanced melanoma and other solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SGN-BB228 and ongoing clinical trials

Detailed information about SGN-BB228 clinical trials